2018 Annual Meeting | C147 - Multiple Sclerosis Therapy: Disease-modifying Treatment II

Date Wednesday 04/25/18

Time 01:00 PM - 03:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) David E. Jones, MD, FAAN, John W. Rose, MD, FAAN

Topic(s)

Learning Objectives Participants should be able to:

1) Know the effects of immunotherapy on Pediatric MS and prospects for formally approved therapy
2) Discuss the status of immunotherapy for Progressive Forms of MS
3) Know the new directions in immunotherapy for MS
4) Evaluate the status of emerging treatments for demyelination

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Tracks Advanced Practice Provider

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse, Trainee, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist

Teaching Styles Didactic

Event Timeline
01:00 PM - 03:00 PM	Speaker	Multiple Sclerosis Therapy: Disease-modifying Treatment II Dennis N. Bourdette, MD, FAAN
02:00 PM - 03:00 PM	Speaker	Pediatric MS Population and Future Directions in Immunotherapy Emmanuelle Waubant, MD, PhD, FAAN

Faculty Disclosures
David E. Jones, MD, FAAN	Dr. Jones has received personal compensation for serving as an employee of Genentech. Dr. Jones has stock in Roche.
John W. Rose, MD, FAAN	The institution of Dr. Rose has received research support from National Multiple Sclerosis Society. The institution of Dr. Rose has received research support from Guthy Jackson Charitable Foundation. The institution of Dr. Rose has received research support from NIH . The institution of Dr. Rose has received research support from VA. The institution of Dr. Rose has received research support from Biogen. The institution of Dr. Rose has received research support from Friends of MS. Dr. Rose has received intellectual property interests from a discovery or technology relating to health care.
Emmanuelle Waubant, MD, PhD, FAAN	Dr. Waubant has received personal compensation in the range of $500-$4,999 for serving as a Consultant for emerald pharmaceuticals. Dr. Waubant has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for elsevier. The institution of Dr. Waubant has received research support from NIH. The institution of Dr. Waubant has received research support from NMSS. The institution of Dr. Waubant has received research support from PCORI. The institution of Dr. Waubant has received research support from Race to Erase MS. The institution of Dr. Waubant has received research support from Roche. The institution of Dr. Waubant has received research support from Biogen. The institution of Dr. Waubant has received research support from Department of Defense. Dr. Waubant has received publishing royalties from a publication relating to health care.
Dennis N. Bourdette, MD, FAAN	Dr. Bourdette has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Magellan Health Care. Dr. Bourdette has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Best Doctor's Inc. Dr. Bourdette has stock in Authobahn Therapeutics. Dr. Bourdette has received intellectual property interests from a discovery or technology relating to health care.